Milestone Pharmaceuticals(US:MIST) Globenewswire·2026-03-20 11:12Core Insights - Milestone Pharmaceuticals reported financial results for Q4 and full year 2025, highlighting the FDA approval and launch of CARDAMYST™ (etripamil) nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) [1][5][6] Financial Performance - The company received a $75 million payment under a Royalty Purchase Agreement related to the FDA approval of CARDAMYST [12] - As of December 31, 2025, Milestone had cash and short-term investments of $106 million, up from $69.7 million in 2024 [13] - The company recorded $1.5 million in revenue for 2025, primarily from a milestone payment related to CARDAMYST's approval [13] - Research and development expenses for 2025 were $18.1 million, an increase from $14.4 million in 2024, driven by higher consulting costs [13][14] - The net loss for Q4 2025 was $17.4 million, or $0.16 per share, compared to a net loss of $12.4 million, or $0.19 per share, in Q4 2024 [14] Product Launch and Market Engagement - The commercial launch of CARDAMYST is tracking or exceeding pre-launch expectations, with a national sales force fully deployed within eight weeks of FDA approval [2][5] - Initial engagement with healthcare providers and payers has been positive, indicating strong demand for CARDAMYST [2][5] - CARDAMYST is the first new treatment option for PSVT in 30 years, with clinical studies showing participants were twice as likely to convert symptomatic PSVT to sinus rhythm compared to placebo [5][6] Regulatory and Development Updates - The marketing authorization application for etripamil nasal spray in Europe has been accepted, with a decision expected by the first half of 2027 [6] - A Phase 3 program for etripamil in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) is planned, following FDA guidance [8] Corporate Updates - David Sandoval was appointed as General Counsel and Chief Compliance Officer, bringing over 15 years of experience in the life sciences sector [10]